Protara Therapeutics (TARA) Amortizatization of Intangibles (2013 - 2026)
Protara Therapeutics (TARA) recorded quarterly Amortizatization of Intangibles of -$190000.0 in Q1 2026, down 109.46% quarter-over-quarter from $2.0 million in Q4 2025, and down 172.24% on a YoY basis from $263000.0 in Q1 2025.
Protara Therapeutics (TARA) Amortizatization of Intangibles (2013 - 2026) Analysis & Trends
Protara Therapeutics' Amortizatization of Intangibles history runs 14 years deep, the most recent figure standing at -$190000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 172.24% year-over-year to -$190000.0; the TTM figure through Mar 2026 stood at $628000.0 (up 194.01% YoY), while the FY2025 annual figure was $1.1 million, up 257.81% from the prior year.
- Amortizatization of Intangibles was -$190000.0 for Q1 2026 at Protara Therapeutics, down from $2.0 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $2.0 million in Q4 2025 to a low of -$1.4 million in Q4 2024.
- Historically, Amortizatization of Intangibles has averaged $52882.4 across 5 years, with a median of $246000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Amortizatization of Intangibles sank 1169.44% in 2023, then soared 807.14% in 2024.
- A 5-year view of Amortizatization of Intangibles shows it stood at $108000.0 in 2022, then tumbled by 1169.44% to -$1.2 million in 2023, then slipped by 24.24% to -$1.4 million in 2024, then surged by 240.0% to $2.0 million in 2025, then plunged by 109.46% to -$190000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at -$190000.0 (Q1 2026), $2.0 million (Q4 2025), and -$396000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Protara Therapeutics | 216.35 Mn | 216.35 Mn | - | -190,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -190,000.00 |
| Mar 31, 2026 | -190,000.00 |
| Dec 31, 2025 | 2.01 Mn |
| Dec 31, 2025 | 2.01 Mn |
| Sep 30, 2025 | -396,000.00 |
| Sep 30, 2025 | -396,000.00 |
| Jun 30, 2025 | -795,000.00 |
| Jun 30, 2025 | -795,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Dec 31, 2024 | -1.44 Mn |
| Dec 31, 2024 | -1.44 Mn |
| Sep 30, 2024 | 254,000.00 |
| Sep 30, 2024 | 254,000.00 |
| Jun 30, 2024 | 250,000.00 |
| Jun 30, 2024 | 250,000.00 |
| Mar 31, 2024 | 246,000.00 |
| Mar 31, 2024 | 246,000.00 |
| Dec 31, 2023 | -1.16 Mn |
| Dec 31, 2023 | -1.16 Mn |